Although pasireotide is FDA-approved for the treatment of hypercortisolism due to corticotroph adenomas, it was not available at the time when this patient was treated and there are no reports of its efficacy in patients with ACTH-secreting pituitary carcinomas [24]. The gene discussed is POMC; the disease is adrenal gland hyperfunction.